

Medic Vision Limited ("Medic Vision" or the "Company")

Issue of Equity

Medic Vision (ASX/AIM: MVH) is pleased to announce that it has issued 1,250,000 ordinary shares ("Ordinary Shares") at A\$0.08 per share to raise A\$100,000, as announced in the Company's interim results released on 2 March 2009.

Application will be made for the 1,250,000 Ordinary Shares to be admitted to trading on AIM and the ASX. See attached. Dealings on AIM are expected to commence on 21 April 2009.

For further information contact:

Ross Horley Tel: +61 3 8508 8288
Managing Director Mob: +61 400 209 899

Medic Vision

Stuart Faulkner / Victoria Milne-Taylor Tel: +44 20 7409 3494

Strand Partners Limited

Ruari McGuirr Tel: +44 20 7628 5582

St Helen's Capital Plc

Background on Medic Vision Limited

Medic Vision is a technology based company specialising in the application of technology for surgical and medical skills training. Medic Vision provides consulting services in the development of skills training centres as well as developing and deploying computer-based surgical and medical high fidelity simulators.

See www.medicvision.com.au for more details

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003.

Name of entity				
Medi	c Vision Limited			
ABN 67 09	99 084 143			
	We (the entity) give ASX the following information.			
Part 1 - All issues You must complete the relevant sections (attach sheets if there is not enough space).				
1	⁺ Class of ⁺ securities issued or to be issued	Ordinary Shares		
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	1,250,000		
3	Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	The new ordinary shares are issued pursuant to a Capital Raising previously advised to the market.		

Appendix 3B Page 2 1/1/2003

⁺ See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?	Yes.	
	If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
5	Issue price or consideration	\$0.08 per share.	
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	N/A	
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	7 April 2009	
		Number	+Class
8	Number and +class of all	106,408,959	Ordinary Shares
O	†securities quoted on ASX (including the securities in clause 2 if applicable)	8,750,173	Options
		<u> </u>	<u> </u>

⁺ See chapter 19 for defined terms.

		Number	+Class
9	Number and +class of all	8,000,000	
J	+securities not quoted on ASX	0,000,000	Options
	(including the securities in clause		
	2 if applicable)		
		1	
10	Dividend policy (in the case of a	Unchanged	
	trust, distribution policy) on the increased capital (interests)		
	mereased capital (interests)		
Da	4.2 Danier :	4- :	
Par	t 2 - Bonus issue or pro	o rata issue	
11	Is security holder approval		
	required?		
12	Is the issue renounceable or non-		1
12	renounceable?		
		<u> </u>	
13	Ratio in which the +securities will		
10	be offered		
14	+Class of +securities to which the		
	offer relates		
15	⁺ Record date to determine		
	entitlements		
		1	
16	Will holdings on different registers		
	(or subregisters) be aggregated for		
	calculating entitlements?	<u> </u>	
17	Policy for deciding entitlements in		1
1/	relation to fractions		
		•	
18	Names of countries in which the		
	entity has +security holders who		
	will not be sent new issue		
	documents		
	Note: Security holders must be told how their entitlements are to be dealt with.		
	Cross reference: rule 7.7.	<u> </u>	
19	Closing date for receipt of		
17	acceptances or renunciations		
	acceptances of renunctations		

Appendix 3B Page 4 1/1/2003

⁺ See chapter 19 for defined terms.

20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	
25	If the issue is contingent on *security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	

⁺ See chapter 19 for defined terms.

32	of their	do *security holders dispose r entitlements (except by sale h a broker)?
33	⁺ Despa	atch date
		Quotation of securities omplete this section if you are applying for quotation of securities
34	Type of	of securities ne)
(a)	✓	
(b)		All other securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Enti	ties tha	at have ticked box 34(a)
Addit	cional se	ecurities forming a new class of securities
Tick to docume		you are providing the information or
35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36		If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over = 1
37		A copy of any trust deed for the additional *securities

Appendix 3B Page 6 1/1/2003

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b) 38 Number of securities for which ⁺quotation is sought 39 Class of +securities for which quotation is sought 40 Do the *securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state: • the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 41 Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security)

42	Number	and	+class	of all +se	ecurities
	quoted	on	ASX	(includi	ing the
	securities in clause 38)				

Number	+Class

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the *securities to be quoted, it has been provided at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.

Appendix 3B Page 8 1/1/2003

⁺ See chapter 19 for defined terms.

- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	Company Secretary.	Date:14 April 2009
Print name:	Mark Licciardo	

⁺ See chapter 19 for defined terms.